Thursday, 17 Aug 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
14 Aug 2017 Social Tocilizumab in Scleroderma completed enrollment in phase III trial - another yr till skin + lung results https://t.co/6QVGeDScbv
08 Aug 2017 Social Tanezumab (MAb against nerve growth factor) is being fast-tracked by FDA as a non-opioid pain reliever. https://t.co/ZXJnS7CmE4
08 Aug 2017 News Therapeutic Update: 5 Questions on Sirukumab FDA Hearing
06 Aug 2017 Social When biosimilars are available, when will you prescribe them?
06 Aug 2017 Social RheumNow Wk in Review is up! FDA hearings on sirukumab, tofacitinib. iTUNES, podcast https://t.co/rX1zLRHUuA & video https://t.co/slvfTJYR1E
03 Aug 2017 News Arthritis Advisory Panel Votes Down Sirukumab
02 Aug 2017 Social FDA Arthritis Advisory Panel votes against (12-2) approval of Sirukumab (IL6 inhib) for use in RA. FDA decision pending.
31 Jul 2017 Social RheumNow Wk in Review is up! Cush talks to new FDA/EMA actions (baricitinib, belimumab, ABA), biosimilar costs, etc https://t.co/o3UHaFVuzd
28 Jul 2017 News NEJM: Actemra Effective in Giant Cell Arteritis
25 Jul 2017 News Baricitinib Derailed by FDA Review
24 Jul 2017 Slide of the day Biosimilar Survey Results from Rheumatologists and Patients
24 Jul 2017 Social Samsung Bioepis launches U.S. sales of Remicade biosmiliar- Renflexis https://t.co/emo6Te0yyW
24 Jul 2017 News Rheumatologists and Patients Concerns over Biosimilars - RheumNow “Live Vote” Results
20 Jul 2017 Social 7 pts w/ Active Refractory Takayasu arteritis Tx w/ RTX w/ mixed results - 3 achieved remission but 4 failed to resp https://t.co/rXSNc6qpTn
13 Jun 2017 News Supreme Court Decision Favors Earlier Biosimilar Adoption
07 Jun 2017 News Upadacitinib Effective in Rheumatoid Arthritis
05 Jun 2017 News Biosimilar Reports – May 2017
25 May 2017 Social RT @RWCSmtg: NOR-SWITCH trial suggests Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13 https://t.co/oTpLD9Qymf #psoriasis…
24 May 2017 News Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
23 May 2017 Social Kevzara-the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition https://t.co/mzIOOhEnMe https://t.co/2U3J2sskum